Drugs / R406
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01598571 | May → Aug 2012 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R406 | “Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose” NCT01598571 ↗ |
| Known as | R940406 | ChEMBL registry synonym — accepted as the source's own label CHEMBL475251 ↗ |
| Known as | Tamatinib | ChEMBL registry synonym — accepted as the source's own label CHEMBL475251 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase SYK inhibitor” CHEMBL475251 ↗ |
| Modality | Small molecule | — CHEMBL475251 ↗ |
| Route | Intravenous | “Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose” NCT01598571 ↗ |
| Target | SYK | “Tyrosine-protein kinase SYK inhibitor” CHEMBL475251 ↗ |